Lakefront Biotherapeutics (LKFT) Return on Capital Employed (2016 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Return on Capital Employed of 11.86% for Q1 2026, up 1680.0% year-on-year from 0.67% in Q1 2025, and up 32.9% on a QoQ basis from 8.92% in Q4 2025.
Lakefront Biotherapeutics (LKFT) Return on Capital Employed (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Return on Capital Employed for 10 consecutive years, with 11.86% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed rose 1680.0% year-over-year to 11.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.86% (up 1680.0% YoY) and the FY2025 annual result came in at 8.15%, up 1297.0% from the prior year.
- Return on Capital Employed climbed to 11.86% in Q1 2026 per LKFT's latest filing, from 8.92% in the prior quarter.
- Over the last five years, Return on Capital Employed for LKFT reached as high as 11.86% in Q1 2026 and fell as low as 11.85% in Q3 2025.
- A 5-year average of 0.08% and a median of 2.2% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 887 bps — and 2026, when it soared 1680 bps.
- Year by year, Return on Capital Employed stood at 5.22% in 2022, then soared by 184 bps to 4.41% in 2023, then tumbled by 132 bps to 1.42% in 2024, then jumped by 727 bps to 8.92% in 2025, then jumped by 33 bps to 11.86% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 11.86%, 8.92%, and 11.85% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | 11.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.86% |
| Dec 31, 2025 | 8.92% |
| Sep 30, 2025 | -11.85% |
| Jun 30, 2025 | -3.53% |
| Mar 31, 2025 | -4.94% |
| Dec 31, 2024 | -1.42% |
| Mar 31, 2024 | 3.93% |
| Dec 31, 2023 | 4.41% |
| Mar 31, 2023 | -2.98% |
| Mar 31, 2022 | -5.22% |
| Dec 31, 2020 | -21.13% |
| Jun 30, 2020 | 4.42% |
| Mar 31, 2020 | 5.14% |
| Dec 31, 2019 | 5.03% |
| Sep 30, 2019 | 10.15% |
| Jun 30, 2019 | -6.35% |
| Mar 31, 2019 | -6.07% |
| Dec 31, 2018 | -4.26% |
| Sep 30, 2018 | -7.51% |
| Jun 30, 2018 | 0.05% |